Literature DB >> 25043031

Coordinated regulation of protein synthesis and degradation by mTORC1.

Yinan Zhang1, Justin Nicholatos1, John R Dreier2, Stéphane J H Ricoult1, Scott B Widenmaier1, Gökhan S Hotamisligil1, David J Kwiatkowski2, Brendan D Manning1.   

Abstract

Eukaryotic cells coordinately control anabolic and catabolic processes to maintain cell and tissue homeostasis. Mechanistic target of rapamycin complex 1 (mTORC1) promotes nutrient-consuming anabolic processes, such as protein synthesis. Here we show that as well as increasing protein synthesis, mTORC1 activation in mouse and human cells also promotes an increased capacity for protein degradation. Cells with activated mTORC1 exhibited elevated levels of intact and active proteasomes through a global increase in the expression of genes encoding proteasome subunits. The increase in proteasome gene expression, cellular proteasome content, and rates of protein turnover downstream of mTORC1 were all dependent on induction of the transcription factor nuclear factor erythroid-derived 2-related factor 1 (NRF1; also known as NFE2L1). Genetic activation of mTORC1 through loss of the tuberous sclerosis complex tumour suppressors, TSC1 or TSC2, or physiological activation of mTORC1 in response to growth factors or feeding resulted in increased NRF1 expression in cells and tissues. We find that this NRF1-dependent elevation in proteasome levels serves to increase the intracellular pool of amino acids, which thereby influences rates of new protein synthesis. Therefore, mTORC1 signalling increases the efficiency of proteasome-mediated protein degradation for both quality control and as a mechanism to supply substrate for sustained protein synthesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25043031      PMCID: PMC4402229          DOI: 10.1038/nature13492

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  27 in total

1.  WebLogo: a sequence logo generator.

Authors:  Gavin E Crooks; Gary Hon; John-Marc Chandonia; Steven E Brenner
Journal:  Genome Res       Date:  2004-06       Impact factor: 9.043

2.  A balance of protein synthesis and proteasome-dependent degradation determines the maintenance of LTP.

Authors:  Rosalina Fonseca; Ramunas M Vabulas; F Ulrich Hartl; Tobias Bonhoeffer; U Valentin Nägerl
Journal:  Neuron       Date:  2006-10-19       Impact factor: 17.173

3.  Clustal W and Clustal X version 2.0.

Authors:  M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins
Journal:  Bioinformatics       Date:  2007-09-10       Impact factor: 6.937

4.  A simplified system for generating recombinant adenoviruses.

Authors:  T C He; S Zhou; L T da Costa; J Yu; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

5.  Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma.

Authors:  Nisreen El-Hashemite; Hongbing Zhang; Elizabeth P Henske; David J Kwiatkowski
Journal:  Lancet       Date:  2003-04-19       Impact factor: 79.321

6.  A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells.

Authors:  David J Kwiatkowski; Hongbing Zhang; Jennifer L Bandura; Kristina M Heiberger; Michael Glogauer; Nisreen el-Hashemite; Hiroaki Onda
Journal:  Hum Mol Genet       Date:  2002-03-01       Impact factor: 6.150

7.  Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis.

Authors:  Umut Ozcan; Lale Ozcan; Erkan Yilmaz; Katrin Düvel; Mustafa Sahin; Brendan D Manning; Gökhan S Hotamisligil
Journal:  Mol Cell       Date:  2008-03-14       Impact factor: 17.970

8.  Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.

Authors:  Hongbing Zhang; Gregor Cicchetti; Hiroaki Onda; Henry B Koon; Kirsten Asrican; Natalia Bajraszewski; Francisca Vazquez; Christopher L Carpenter; David J Kwiatkowski
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

9.  Selective coactivator interactions in gene activation by SREBP-1a and -1c.

Authors:  Julia I Toth; Shrimati Datta; Jyoti N Athanikar; Leonard P Freedman; Timothy F Osborne
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 10.  The mammalian unfolded protein response.

Authors:  Martin Schröder; Randal J Kaufman
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

View more
  141 in total

Review 1.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

2.  The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability.

Authors:  Jacky Chung; Daniel E Bauer; Alireza Ghamari; Christopher P Nizzi; Kathryn M Deck; Paul D Kingsley; Yvette Y Yien; Nicholas C Huston; Caiyong Chen; Iman J Schultz; Arthur J Dalton; Johannes G Wittig; James Palis; Stuart H Orkin; Harvey F Lodish; Richard S Eisenstein; Alan B Cantor; Barry H Paw
Journal:  Sci Signal       Date:  2015-04-14       Impact factor: 8.192

Review 3.  Oncogenes strike a balance between cellular growth and homeostasis.

Authors:  Bo Qiu; M Celeste Simon
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

4.  The switch-like expression of heme-regulated kinase 1 mediates neuronal proteostasis following proteasome inhibition.

Authors:  Beatriz Alvarez-Castelao; Susanne Tom Dieck; Claudia M Fusco; Paul Donlin-Asp; Julio D Perez; Erin M Schuman
Journal:  Elife       Date:  2020-04-24       Impact factor: 8.140

Review 5.  Insulin Regulation of Proteostasis and Clinical Implications.

Authors:  Haleigh A James; Brian T O'Neill; K Sreekumaran Nair
Journal:  Cell Metab       Date:  2017-07-14       Impact factor: 27.287

6.  mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle.

Authors:  Issam Ben-Sahra; Gerta Hoxhaj; Stéphane J H Ricoult; John M Asara; Brendan D Manning
Journal:  Science       Date:  2016-02-12       Impact factor: 47.728

7.  Analysis of TSC1 mutation spectrum in mucosal melanoma.

Authors:  Meng Ma; Jie Dai; Tianxiao Xu; Sifan Yu; Huan Yu; Huan Tang; Junya Yan; Xiaowen Wu; Jiayi Yu; Zhihong Chi; Lu Si; Chuanliang Cui; Xinan Sheng; Yan Kong; Jun Guo
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-28       Impact factor: 4.553

8.  p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.

Authors:  Hilaire C Lam; Christian V Baglini; Alicia Llorente Lope; Andrey A Parkhitko; Heng-Jia Liu; Nicola Alesi; Izabela A Malinowska; Darius Ebrahimi-Fakhari; Afshin Saffari; Jane J Yu; Ana Pereira; Damir Khabibullin; Barbara Ogorek; Julie Nijmeh; Taylor Kavanagh; Adam Handen; Stephen Y Chan; John M Asara; William M Oldham; Maria T Diaz-Meco; Jorge Moscat; Mustafa Sahin; Carmen Priolo; Elizabeth P Henske
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

9.  Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway.

Authors:  Jia Tong; Qing Yu; Wenbin Xu; Wenjun Yu; Chao Wu; Yingli Wu; Hua Yan
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

10.  Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth.

Authors:  Sathish K R Padi; Neha Singh; Jeremiah J Bearss; Virginie Olive; Jin H Song; Marina Cardó-Vila; Andrew S Kraft; Koichi Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.